MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    The Effects of Apomorphine infusion on Head ptosis, a case report

    O. Skogar (Stockholm, Sweden)

    Objective: Sustained Effects of Apomorphine infusion on Head Ptosis, a case report Background: IntroductionHead ptosis (Hp) results from weakness of the neck extensor, or increased…
  • 2019 International Congress

    Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens

    F. Stocchi, W. Poewe, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

    Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…
  • 2019 International Congress

    A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson’s disease dementia

    P. Svenningsson, P. Odin, N. Dizdar, F. Bergquist, A. Johansson, D. Nyholm, K. Wictorin, J. Tedroff (Uppsala, Sweden)

    Objective: The primary objective was to investigate the safety and tolerability of IRL752 in PD patients with dementia in a randomized controlled trial. Secondary outcome…
  • 2019 International Congress

    Spectrum of motor complications in advanced Parkinson’s disease: data from a large Romanian case series evaluated for suitability for device aided therapy

    J. Szász, V. Constantin, K. Orbán, L. Bancu, D. Georgescu, J. Szederjesi, A. Rácz, I. Mihály, S. Szatmári (Tirgu Mures, Romania)

    Objective: The objective was to describe the spectrum of motor complications in a large cohort of patients with advanced Parkinson’s Disease (APD) who received at…
  • 2019 International Congress

    A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1

    A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

    Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…
  • 2019 International Congress

    An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2

    A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

    Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…
  • 2019 International Congress

    Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data

    C. Tanner, R. Pahwa, V. Vandevoorde, K. Wehrman, R. Elfont (San Francisco, CA, USA)

    Objective: To assess the real-world safety profile of Gocovri® (amantadine) extended release capsules one year post-launch. Background: Gocovri received FDA approval in August 2017 for…
  • 2019 International Congress

    Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease

    I. Taravini, G. Gomez, L. Tribbia, A. Cura, R. Rivero, M. Bernardi, J. Ferrario, B. Baldi-Coronel, O. Gershanik, E. Gatto (Gualeguaychú, Argentina)

    Objective: We set to investigate the possible neuroprotective effect of yerba mate (YM) consumption on dopaminergic neurons in a mice model of Parkinson’s disease (PD). Background: The motor…
  • 2019 International Congress

    Short term use of bromocriptine for treatment of Parkinson’s disease during pregnancy

    D. Taylor, P. Lewitt (West Bloomfield, MI, USA)

    Objective: Few reports describe experience with treatment of Parkinson's disease [PD] during pregnancy. About 5% of the population with PD are young onset (onset prior…
  • 2019 International Congress

    Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017

    L. Tönges, D. Bartig, C. Krogias, D. Richter (Bochum, Germany)

    Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…
  • « Previous Page
  • 1
  • …
  • 1213
  • 1214
  • 1215
  • 1216
  • 1217
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley